Market Access & Pricing Strategy

Senior market access &
pricing leadership
for high-stakes launches

I work with pre-commercial biotech teams and market access consultancies navigating high-stakes pricing and access decisions (EU JCA, IRP sequencing, HTA governance, and pricing systems) where strategic clarity at the right moment changes outcomes.

Get in touch Who I work with →
10+ Years in global market access & pricing
60+ Markets covered across IRP portfolios
Global HTA & payer expertise: EU, US, Japan, China, Canada, MENA

What I do

Core capabilities

Global pricing strategy

Launch price policy (gross & net floors), IRP cascade modelling, launch sequence optimisation, analogue benchmarking, and international price business cases across 60+ markets.

IRP sequencing Net floor analysis NPV modelling

Market access & HTA strategy

EU JCA dossier strategy, PICO structuring, comparator strategy, ITC oversight, cost-effectiveness modelling supervision, and submission positioning for NICE, G-BA, HAS, and CDA-AMC.

EU JCA PICO strategy GVD development

Pricing governance & systems

Design and implementation of global pricing governance frameworks: approval thresholds, escalation pathways, pricing committee structures, and systems integration across NAVLIN and EVERSANA platforms.

NAVLIN EVERSANA GTN waterfall

Launch readiness & pipeline advisory

Fractional market access and pricing leadership for pre-commercial biotechs: evidence gap analysis, IEP development, Phase II/III trial design implications, and IRA/MFN ex-US net price impact sizing.

Phase II/III IRA / MFN OUS expansion

Outcomes-based & gene therapy pricing

One-time payment models, outcomes-based instalment structures, annuity frameworks, and payer-aligned value demonstration for cell and gene therapy assets navigating complex reimbursement environments.

CGT pricing OBA structures Rare disease
Profile photo

"10 years across AbbVie, Allergan, and leading market access consultancies including IQVIA, IHS Markit, and EVERSANA. Pricing governance frameworks built and adopted across 60+ markets. Executive-level presentations to SVP and C-suite. EU JCA strategy from Phase II through submission. Japan (PMDA) and China (NMPA) market access experience. PharmD and MPH trained, with advanced HTA and pricing methodology qualifications from Sheffield, Johns Hopkins, and Erasmus."

Moez Katet, Founder · Based in London, UK  ·  Available for engagements across UK, EU, US, Japan, China, and international markets

Who I work with

Three types of client, one common need

US Biotech : OUS expansion

US-based biotechs preparing to take their asset international for the first time

Many US biotechs with strong domestic commercial positions lack the in-house expertise to navigate EU and international market access. I build the OUS market access and pricing foundation (EU JCA readiness, IRP strategy, HTA positioning) so that ex-US launch doesn't erode the US price or delay access.

EU JCA · IRP risk · OUS launch strategy · Payer value proposition
Biotech & Pharma: Fractional

Pre-commercial teams that need senior market access leadership without a full-time hire

Phase II/III biotechs preparing for their first major launch often lack in-house HTA and pricing expertise at the exact moment they need it most. I step in as a fractional Global Market Access & Pricing Director to build the strategy, challenge assumptions, and bulletproof the commercial case before out-licensing or approval.

Typically 3–4 days per month · Retainer or project basis · Oncology, rare disease & CGT
Consultancies & Agencies

Market access consultancies that need a trusted senior subcontractor

Boutique market access agencies frequently win large pricing and HTA mandates that require more senior bandwidth than their team can absorb. I work as an embedded senior partner, handling the strategic market access and pricing portions of client briefs with director-level quality and full discretion.

Project or retainer · Fully confidential · EU and international mandates
Oncology Rare Disease Cell & Gene Therapy Specialty Care EU JCA IRP Sequencing NICE · G-BA · HAS PMDA · NMPA NAVLIN · EVERSANA

Currently accepting new engagements. I work with a small number of clients at any one time to ensure focused, senior attention on every mandate.

How I engage

Simple from the first conversation

01

Initial conversation

A 45-minute scoping call, no commitment required. You explain the challenge, I tell you honestly whether and how I can help.

02

Proposal

A clear, one-page engagement summary covering scope, deliverables, timeline, and fees. No ambiguity.

03

Engagement

Work begins. Structured updates throughout. Direct access to me at every stage.

Contact

Let's talk. I'm Moez Katet.

Whether you're a biotech building your first global pricing strategy or a consultancy looking for a senior subcontract partner, I'm happy to start with a conversation.

Email
moez.katet@wegophar.com
LinkedIn
WeGoPhar →
Location
London, United Kingdom
Availability
Open to new mandates

Engagements typically begin with a no-commitment scoping call.